Amedisys Stock Today
| AMED Stock | USD 98.25 0.50 0.51% |
Performance8 of 100
| Odds Of DistressLess than 16
|
Amedisys is trading at 98.25 as of the 26th of July 2024, a 0.51 percent increase since the beginning of the trading day. The stock's lowest day price was 97.63. Amedisys has less than a 16 % chance of experiencing some financial distress in the next two years of operation, but did not have a good performance during the last 90 trading days. Equity ratings for Amedisys are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 27th of April 2024 and ending today, the 26th of July 2024. Click here to learn more.
Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. Amedisys, Inc. was incorporated in 1982 and is headquartered in Baton Rouge, Louisiana. Amedisys operates under Medical Care Facilities classification in the United States and is traded on NASDAQ Exchange. The company has 32.74 M outstanding shares of which 1.98 M shares are presently shorted by private and institutional investors with about 4.16 trading days to cover. More on Amedisys
Moving against Amedisys Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Amedisys Stock Highlights
| CEO President | Richard Ashworth |
| Old Name | Amedeo Resources Plc |
| Business Concentration | Health Care Providers & Services, Health Care Equipment & Services, Health Care, NASDAQ Composite, SP Midcap 400, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Health Care Providers & Services, Medical Care Facilities, Healthcare (View all Sectors) |
Amedisys (AMED) is traded on NASDAQ Exchange in USA. It is located in 3854 American Way, Baton Rouge, LA, United States, 70816 and employs 18,700 people. Amedisys is listed under Health Care Providers & Services category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 3.2 B. Amedisys conducts business under Health Care Providers & Services sector and is part of Health Care industry. The entity has 32.74 M outstanding shares of which 1.98 M shares are presently shorted by private and institutional investors with about 4.16 trading days to cover.
Amedisys currently holds about 17.96 M in cash with 137.19 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.55.
Check Amedisys Probability Of Bankruptcy
Ownership AllocationAmedisys holds a total of 32.74 Million outstanding shares. The majority of Amedisys outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Amedisys to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Amedisys. Please pay attention to any change in the institutional holdings of Amedisys as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Amedisys Ownership Details
Amedisys Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Amedisys market risk premium is the additional return an investor will receive from holding Amedisys long position in a well-diversified portfolio.
| Risk Adjusted Performance | 0.0763 | |||
| Jensen Alpha | 0.1209 | |||
| Total Risk Alpha | (0.01) | |||
| Sortino Ratio | 0.0308 |
Amedisys Stock Against Markets
Amedisys Corporate Management
| John Nugent | Chief Officer | Profile | |
| Pete Hartley | CTO Systems | Profile | |
| Kendra Kimmons | VP Relations | Profile | |
| Jennifer Griffin | Deputy VP | Profile | |
| Janet Britt | VP Collections | Profile |
Already Invested in Amedisys?
The danger of trading Amedisys is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Amedisys is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Amedisys. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Amedisys is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Information and Resources on Investing in Amedisys Stock
When determining whether Amedisys is a strong investment it is important to analyze Amedisys' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Amedisys' future performance. For an informed investment choice regarding Amedisys Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Amedisys. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. For information on how to trade Amedisys Stock refer to our How to Trade Amedisys Stock guide.You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amedisys. If investors know Amedisys will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amedisys listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Amedisys is measured differently than its book value, which is the value of Amedisys that is recorded on the company's balance sheet. Investors also form their own opinion of Amedisys' value that differs from its market value or its book value, called intrinsic value, which is Amedisys' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amedisys' market value can be influenced by many factors that don't directly affect Amedisys' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amedisys' value and its price as these two are different measures arrived at by different means. Investors typically determine if Amedisys is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amedisys' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.